80
Participants
Start Date
September 30, 2002
Study Completion Date
March 31, 2003
OSI-211 (Liposomal Lurtotecan)
NYU- Kaplan Comprehensive Cancer Center, New York
The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville
St Chad's Unit, Birmingham
Beatson Oncology Centre, Glasgow
Royal Surrey County Hospital, Guildford, Surrey
Royal Marsden NHS Trust, London
Northern Centre for Cancer Research, Newcastle General Hospital, Newcastle upon Tyne
Mount Vernon Hospital, Northwood, Middlesex
CRC Department of Medical Oncology, Sutton Surrey
Taunton & Somerset Hospital, Taunton
Medical Oncology Unit, Torbay District General Hospital, Torquay
Lead Sponsor
Collaborators (1)
OSI Pharmaceuticals
INDUSTRY
Astellas Pharma Inc
INDUSTRY